Imaging study comparing benign and cancerous kidney growths using advanced MRI scans

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have a kidney mass that doctors think may be harmless or cancer. They will have special MRI scans.

Age

Over 18 years old

Sex

All sexes

Disease stage

A kidney (renal) mass that is suspected on scans or confirmed by tests to be benign or malignant.

Main reasons for not taking part

• Cannot have or tolerate an MRI scan
• Pregnant or breast-feeding women
• Significant heart, lung or nervous system disease
• Lab test results that could affect the study results
• Other significant medical or psychiatric history, as judged by the investigators

The registry criteria, word for word

What the trial wants to find out

The aim of this study is to develop techniques for non-invasive imaging of biology in participants with benign or malignant renal masses based on the novel scanning MRI techniques, including recently invented Hyperpolarised MRI, deuterium metabolic imaging and sodium MRI. This imaging study will: 1) acquire imaging data from human tissues following the injection of hyperpolarised 13C pyruvate and use 13C-MRI to monitor changes in the ratio of 13C-lactate to 13C-pyruvate; 2) acquire imaging data from human tissues using Sodium MRI or 3) acquire imaging data from human tissues following the oral consumable of deuterated glucose. Data acquired during this physiological study will be used to optimise future imaging protocols.In the UK and possibly in other countries, there are some patients with renal masses that are over treated or undergo unnecessary procedures such as surgery or biopsies, as they are thought to have a malignant tumour or a more aggressive tumour but after the procedure it is found that the mass was benign. The aim of this study is to determine whether one or all of these imaging techniques can differentiate between benign and malignant renal masses with the view to developing the techniques further and hopefully reducing the need for over treatment or unnecessary procedures in patients with benign masses.

The 3 groups in the trial

• Hyperpolarised MRIOther group

  Hyperpolarised 13C-pyruvate injection while laying in the MRI scanner. Non-radioactive, no risk, approved for use in humans.

• Sodium MRIOther group

  MRI procedure as a regular MRI scan, the only change is us using a different sort of equipment so we are able to detect sodium.

• Deuterium metabolic imaging (DMI) MRIOther group

  Drink of a sugar drink 90min before the MRI scan. Non-radioactive, no risk, approved for use in humans.